Boyle Dana sold $140K of LQDA

Boyle Dana (Chief Accounting Officer) sold 1,600 shares of Liquidia Corp (LQDA) at $87.53 ($0.14M total) on 2026-07-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Boyle Dana
Published Jul 29, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 29, 2026, 8:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LQDA
Neutral
high confidence
Mentioned
$LQDA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The newest fact is the specific sale size, price, and post-transaction holdings, but it does not include any new company performance, guidance, or regulatory development.

02

Market read

Primarily a compliance disclosure; any trading impact is likely limited to short-term sentiment rather than fundamentals.

03

What to watch

Traders may over-weight insider sales; without additional context (e.g., multiple concurrent sales, option exercises, or company disclosures), the signal is weak.

Relevance 3/10Novelty 2/10Timing: Filed on 2026-07-29 after-hours, reflecting the 2026-07-27 sale.

Background

The article is an SEC Form 4 insider transaction disclosure for Liquidia Corp.

Company-level read

Ticker impact

$LQDANeutralHigh confidence
Context

Form 4 shows Boyle Dana, Liquidia’s Chief Accounting Officer, sold 1,600 shares at $87.53 on 2026-07-27 under a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely limited to short-lived sentiment around insider selling.

Evidence & confidence

The filing is an open-market sale by an accounting officer, explicitly under a pre-arranged 10b5-1 plan, with no accompanying company news or guidance change.

Market effects

No sector read-across; this is company-specific insider transaction reporting.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect liquidity needs rather than bearish expectations, so any negative tape reaction may fade quickly.

Key entities

  • Liquidia Corp

    Company whose insider transaction is disclosed on Form 4.

  • Boyle Dana

    Chief Accounting Officer who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia Corporation (LQDA) reported Q3 2026 earnings of 80 cents per share, exceeding estimates. Revenue surged 314.6% YoY to $225.3M, driven by strong Yutrepia sales. The company settled litigation with United Therapeutics, incurring a $389.7M charge. LQDA stock gained 7.37% post-announcement. Management remains optimistic about Yutrepia's growth and pipeline advancements.

$LQDAMed

Wells Fargo raises Liquidia stock price target on improved outlook

Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.

$LQDAHighAI 8/10

Liquidia (LQDA) Q3 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q3 2026 net product sales of $222.7M, up 31%. PAH diagnoses drove growth, with 70% of prescriptions in September. October saw record shipments post-settlement. Referrals held steady, and prescriber base expanded. YUTREPIA's flexibility supports market share gains in PAH. Financials show strong revenue growth, with adjusted EBITDA at $140.5M. The company plans to fund operations without raising capital.

$LQDAMed

Liquidia Q3 Earnings Call Highlights

Liquidia (LQDA) reported Q3 adjusted EBITDA of $140.5M, up sequentially, with $396.1M in cash. The company faces a $389.7M settlement, payable by April 2027. Liquidia plans clinical trials for YUTREPIA and L606, with data expected in 2027-2029. Management affirmed no capital raise is needed and no royalties to United Therapeutics post-settlement.